- CSR Summary Not Available
- NCT01973387
- Primary Citation
- Data Specification Not Yet Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameIbrutinibProduct NameIMBRUVICA®Therapeutic AreaCancers and Other NeoplasmsEnrollment159% Female27.4%% WhiteN/A
Product ClassKinase InhibitorsSponsor Protocol NumberPCI-32765CLL3002Data PartnerJohnson & JohnsonCondition StudiedChronic LymphocyticMean/Median Age (Years)63.6
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available